Total Payments
$2,059
2024 Payments
$1,164
Companies
12
Transactions
56
Medicare Patients
2,127
Medicare Billing
$264,912
Payment Breakdown by Category
Other$1,164 (56.5%)
Education$482.44 (23.4%)
Food & Beverage$412.73 (20.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Long term medical supply or device loan | $1,164 | 12 | 56.5% |
| Education | $482.44 | 32 | 23.4% |
| Food and Beverage | $412.73 | 12 | 20.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,164 | 12 | $0 (2024) |
| PFIZER INC. | $444.24 | 28 | $0 (2023) |
| Daiichi Sankyo Inc. | $133.18 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $119.76 | 1 | $0 (2018) |
| Lilly USA, LLC | $52.82 | 4 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $48.42 | 3 | $0 (2020) |
| TESARO, Inc. | $24.04 | 1 | $0 (2018) |
| Pharmacyclics LLC, An AbbVie Company | $20.67 | 1 | $0 (2019) |
| Clovis Oncology, Inc. | $15.28 | 2 | $0 (2019) |
| AbbVie, Inc. | $13.84 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,164 | 12 | Novartis Pharmaceuticals Corporation ($1,164) |
| 2023 | $221.25 | 14 | PFIZER INC. ($221.25) |
| 2022 | $208.10 | 13 | PFIZER INC. ($208.10) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $35.92 | 2 | AstraZeneca Pharmaceuticals LP ($35.92) |
| 2019 | $85.84 | 7 | Pharmacyclics LLC, An AbbVie Company ($20.67) |
| 2018 | $155.45 | 3 | Regeneron Healthcare Solutions, Inc. ($119.76) |
| 2017 | $176.69 | 4 | Daiichi Sankyo Inc. ($133.18) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 02/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.66 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.66 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.20 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 568 | 842 | $177,021 | $64,165 |
| 2022 | 9 | 554 | 925 | $172,911 | $67,196 |
| 2021 | 10 | 564 | 998 | $168,039 | $75,468 |
| 2020 | 9 | 441 | 850 | $149,794 | $58,083 |
Total Patients
2,127
Total Services
3,615
Medicare Billing
$264,912
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 276 | 437 | $83,223 | $28,448 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 88 | 129 | $36,094 | $13,310 | 36.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $15,918 | $5,935 | 37.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 51 | $10,921 | $4,682 | 42.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 71 | $10,330 | $4,303 | 41.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $9,843 | $3,613 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 45 | $5,816 | $1,777 | 30.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $2,692 | $1,103 | 41.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 17 | 26 | $2,184 | $995.02 | 45.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 275 | 545 | $94,080 | $35,462 | 37.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $16,784 | $6,962 | 41.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 48 | $11,794 | $5,223 | 44.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 67 | $13,037 | $5,078 | 39.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 44 | 93 | $12,540 | $5,002 | 39.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 31 | 32 | $12,074 | $4,815 | 39.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 22 | $5,481 | $2,126 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 45 | $5,261 | $1,811 | 34.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 17 | 24 | $1,860 | $716.22 | 38.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 288 | 613 | $93,176 | $41,698 | 44.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 63 | 63 | $20,538 | $8,553 | 41.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 43 | 57 | $12,255 | $6,214 | 50.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 44 | 105 | $12,600 | $5,593 | 44.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 58 | $10,150 | $4,660 | 45.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 28 | 28 | $9,100 | $4,313 | 47.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 16 | 16 | $3,600 | $1,618 | 44.9% |
About Dr. Lara Theobald, MD
Dr. Lara Theobald, MD is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1376690271.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lara Theobald, MD has received a total of $2,059 in payments from pharmaceutical and medical device companies, with $1,164 received in 2024. These payments were reported across 56 transactions from 12 companies. The most common payment nature is "Long term medical supply or device loan" ($1,164).
As a Medicare-enrolled provider, Theobald has provided services to 2,127 Medicare beneficiaries, totaling 3,615 services with total Medicare billing of $264,912. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 01/04/2007
- Last Updated 06/27/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1376690271
Products in Payments
- KISQALI (Drug) $1,164
- IBRANCE (Drug) $444.24
- Morphabond ER (Drug) $133.18
- PRALUENT ALIROCUMAB INJECTION (Biological) $119.76
- CYRAMZA (Drug) $24.34
- ZEJULA (Drug) $24.04
- Imbruvica (Drug) $20.67
- ERBITUX (Drug) $15.93
- Rubraca (Drug) $15.28
- Venclexta (Drug) $13.84
- ALIMTA (Drug) $12.55
- TAGRISSO (Drug) $12.50
- CALQUENCE (Drug) $11.41
- Cabometyx (Drug) $11.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791